20 articles
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
German researchers tested whether 4g daily taurine could slow aging processes in adults 55-75 over 6 months of supplementation.
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
Study tests whether omega-3 rich flax oil enhances resistance training benefits for muscle mass and inflammation in older adults.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
Researchers used retinal imaging to detect brain amyloid and tested whether telomerase activation could reduce Alzheimer's markers.
12-week trial tested omega-3 rich camelina oil snacks in 91 healthy adults over 65 for anti-inflammatory effects.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
12-week omega-3 trial tested whether fish oil could reverse accelerated immune system aging in HIV-infected older adults.
5-month trial tracked omega-3 absorption and washout patterns in young vs older adults to optimize dosing strategies.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
Small trial compared EPA vs DHA effects on inflammation markers and lipid profiles in metabolic syndrome patients over 4+ years.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
